Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Clin Neurosci. 2013 Nov;20(11):1482-5. doi: 10.1016/j.jocn.2013.02.041. Epub 2013 Sep 13.

Memantine hydrochloride in the treatment of dementia subtypes.

Author information

  • 1Department of Neurology, Beijing Hospital, Ministry of Health, No. 1, Dahua Road, Dongcheng District, Beijing, China. Electronic address: pengdantao@medmail.com.cn.

Abstract

Memantine hydrochloride is a first-line therapeutic drug approved by the US Food and Drug Administration for the management of moderate to severe Alzheimer's disease (AD). We conducted a review of the literature to determine the changes to the central glutamatergic neurotransmitter system in dementia subtypes and the available clinical evidence regarding the use of memantine in the treatment of different dementia subtypes. We conclude from our review that memantine may be an effective therapeutic option in managing AD, frontotemporal dementia, dementia with Lewy bodies, Parkinson's disease dementia and vascular dementia. When a diagnosis of the dementia subtype cannot be clearly identified or when there is no clear therapeutic option, memantine may be simple and safe.

Copyright © 2013 Elsevier Ltd. All rights reserved.

KEYWORDS:

Alzheimer’s disease; Dementia; Dementia subtypes; Memantine

PMID:
24035650
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk